Skip to main content
. Author manuscript; available in PMC: 2015 Jun 1.
Published in final edited form as: Ann Rheum Dis. 2014 Feb 23;74(6):1284–1292. doi: 10.1136/annrheumdis-2013-204782

Figure 2. IL-17A induces an IL-17R+CD11b+Gr1lowRANK+CSF-1R+ osteoclast precursor and exacerbates RANKL-mediated osteoclastogenesis.

Figure 2

a) H&E-stained decalcified limb samples from GFP MC and IL-17A MC-injected mice at 7 weeks post gene transfer showing no signs of synovial inflammation. Representative data from 4 experiments and 35 mice. b) Micro-CT 3D rendered images of paw anterior views post GFP-MC or IL-17A MC injection. Data representative of 4 experiments and a total of 10 analyzed mice. Serum c) TRAP5b and d) RANKL 3 weeks post gene transfer (each dot represents individual mice, data pooled from 3 experiments, p<0.05 and NS respectively using students unpaired t-test). Flow cytometric analysis of e) bone marrow cells and f) splenocytes derived from GFP or IL-17A gene transfer at day 3 depicting RANK+ and CSF-1R+ cells. Data is representative data of 3 experiments using 3 mice per experiment. g) Serum TRAP5b of mice 11 and 38 days post RANKL MC (0.05 μg) and GFP MC transfer in C57BL/6 mice overexpressing IL-17A or GFP for 30 days (each dot represent individual mice, data pooled from 2 experiments, students unpaired t-test).